Citations

Clear

97 citation(s) found for "Pereira, Naveen".

Early identification of rare disease using deep phenotyping of electronic health records
Tunstall, Tate, Ng, Pauline C, Meyers, Lindsay, Coldagelli, Maria-Renee, Yang, Lu, Pereira, Naveen, Osundiji, Mayowa, Im, Kate, Kumar, Akash , Rabinowitz, Matt, Tunstall, Tate, Ng, Pauline C. , Yang, Lu

Mayo Clinic

No container title available | September 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.11.26362811 Get It

Abstract Patients with rare genetic disorders often wait years for a correct diagnosis, highlighting the urgent need for early and efficient triage for those at risk. Electronic health records (EHRs) are rich in useful information, yet the extent to which this data is sufficient to generate prediagnostic signals is uncertain. We trained machine learning models on billing codes and phenotypes extracted from clinical notes and applied these across eight conditions in a longitudinal cohort of roughly 3 million patient records from the Mayo Clinic, seeking early identification of conditions. The number of patients identified early varied by condition, ranging from 10% to 89% at 99% specificity. Median lead times exceeded one year prior to the first diagnostic billing code for most conditions, including Fabry disease (1,408 days), hereditary angioedema (2,755 days), neurofibromatosis type 1 (1,067 days), and hereditary hemorrhagic telangiectasia (2,320 days). We show that ML models trained on EHR data can prioritize patients for clinician review and confirmatory genetic testing and that the integration of diverse phenotypic data sources provides superior predictive value.
Machine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCI
Grant, Caroline W. , Ingraham, Brenden , Lennon, Ryan J. , Raina, Anvi , Tian, Shulan , Kowlgi, Gurukripa N. , Cavallari, Larisa H. , Lee, Craig R. , Beitelshees, Amber L. , Angiolillo, Dominick J. , Rossi, J. , Stouffer, George A. , Klee, Eric W. , Gulati, Rajiv, Rihal, Charanjit S. , Farkouh, Michael E. , Athreya, Arjun , Pereira, Naveen L. , Beitelshees, Amber L. , Ingraham, Brenden S , Kowlgi, Narayan G , Franchi, Francesco , Duarte, Julio D , Rossi, Joseph S , Stouffer, George A , Klee, Eric W , Rihal, Charanjit S. , Farkouh, Michael E , Athreya, Arjun P , Pereira, Naveen L , Angiolillo, Dominick J , Cavallari, Larisa H , Tian, Shulan , Lennon, Ryan J. , Duarte, Julio D. , Gulati, Rajiv , Athreya, Arjun P.

Mayo Clinic

Clinical and Translational Science | July 10, 2026 | Volume: 19 | Issue: 7 | Pages: No page available

10.1111/cts.70655 | PMID 42427167 Get It

ABSTRACT Ischemic events after contemporary percutaneous coronary intervention (PCI) are uncommon but carry high morbidity/mortality. Identifying patients at highest risk is critical to guide dual antiplatelet therapy (DAPT) intensity while minimizing bleeding. Current machine learning (ML) model‐developed risk scores do not incorporate pharmacogenetic data. To develop and externally validate ML models that integrate clinical, demographic, and CYP2C19 genetic information to predict 1‐year ischemic outcomes post‐PCI to refine clinical decision making. We analyzed 8317 patients from TAILOR‐PCI trial ( n = 4572) and the Precision PCI registry ( n = 3745). The outcome was a composite of cardiovascular death, myocardial infarction, stroke, and stent thrombosis at 1 year. Boruta feature selection identified 11 predictors. Multiple ML algorithms were trained in TAILOR‐PCI and validated in Precision PCI using cross‐validation and synthetic minority oversampling (SMOTE). Model performance was assessed by area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. The best external performance was achieved with a support vector machine (SVM, polynomial kernel) (AUC 0.667; sensitivity 0.871; specificity 0.282), while XGBoost provided a more balanced profile (AUC 0.619; sensitivity 0.442; specificity 0.688). Variable importance for the SVM polynomial model demonstrated that all 11 included Boruta feature selected predictors had relatively high importance (> 75). ML models trained on large clinical trial and real‐world registry datasets can help identify the small subset of patients at high ischemic risk after PCI. This distinction is of relevance because ischemic events are rare, and most patients may safely de‐escalate DAPT to reduce bleeding risk while maintaining ischemic protection through a multimodal approach to risk stratification. Trial Registration: TAILOR‐PCI URL: https://clinicaltrials.gov/ct2/show/NCT01742117
CDCP1 Deletion Protects Against Pressure Overload-Induced Cardiac Dysfunction and Fibrosis in Mice
Pereira, Naveen, Ghazal, Rachad, wang, Min, Cao, Jenny Jia Ling, Wang, Li , Sherman, William , John, August, Vyas, Hridyanshu , Roos, Carolyn, Huang, Runqing, Ördög, Tamás , Trussoni, Christy, Lim, Do Young , Sinagra, Gianfranco, Weinshilboum, Richard M. , Liu, Duan , Lambert, Laura , Miller, Jordan , Tschumperlin, Daniel, Srinivas, Akshatha N. , Sherman, Will A , Ordog, Tamas , Wang, Chen , Baker, Darren J , Weinshilboum, Richard M. , Liu, Duan , Lambert, Laura J, Pereira, Naveen, Ghazal, Rachad , Cao, Jenny Jia Ling , Wang, Li, Marín-Goñi, Irene , Wang, Chen , Trussoni, Christy E. , Baker, Darren J. , Sinagra, Gianfranco , Tschumperlin, Daniel J.

Mayo Clinic

No container title available | May 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9236741/v1 | PMID 42147194 Get It

Abstract Human genomic studies link reduced CUB domain-containing protein 1 (CDCP1) expression with myocardial recovery in heart failure. While CDCP1 regulates cardiac fibroblast proliferation in vitro, it’s in vivo role in cardiac fibrosis remains unclear. Using a Cdcp1 -knockout (KO) angiotensin II/phenylephrine mouse model, we show that Cdcp1 deletion reduces echocardiographic left ventricular mass, histologic cardiac fibrosis, and pro-fibrotic gene expression, along with decreased fibroblast activation and inflammatory markers. Spatial transcriptomics identified a pressure overload–expanded fibroblast subpopulation enriched for growth factor and TGF-β signaling (FB5), which was markedly attenuated in Cdcp1 -KO hearts, alongside reduction of a pro-inflammatory cardiomyocyte subtype (CM4). Complementary studies in human ventricular fibroblasts demonstrate that CDCP1 knockdown reduced extracellular matrix gene expression and collagen I deposition. These findings establish CDCP1 as a regulator of cardiac fibrotic remodeling in vivo and open avenues for its further investigation as a potential therapeutic target.
Monogenic and Polygenic Contributions to Cardiomyopathy and Heart Failure Across Diverse Populations
Pereira, Naveen, Tan, Jia W. , Dikilitas, Ozan , Figueiral, Marta , Tan-Arroyo, Jennifer , Olson, Rory, Srinivas, Akshatha, (227567), Yao Xiao, Venettozzi, Marcella, Vairo, Filippo Pinto e, Schaid, DJ, Klee, Eric W., Dikilitas, Ozan , Olson, Rory J. , Panwar, Deepak, Cao, Jenny , Srinivas, Akshatha, Klee, Eric W. , Tan, Jia Wen

Mayo Clinic

No container title available | May 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9581360/v1 Get It

Abstract Pathogenic variants in cardiomyopathy genes confer substantial disease risk, yet clinical penetrance varies widely. The population-level prevalence, age-specific penetrance, and the extent to which polygenic susceptibility modifies disease risk across diverse ancestries remain poorly defined. This population-based cohort study leveraged genome sequencing and linked electronic health record data from the All of Us Research Program (n=414,830). This study found that P/LP variants in cardiomyopathy-associated genes were present in 0.91% of participants (95% CI, 0.88%–0.94%), with similar prevalence across ancestry groups. Compared with non-carriers, variant carriers had significantly higher odds of all-cause heart failure (ACHF, OR, 2.58; 95% CI, 2.31–2.89), non-ischemic heart failure (NIHF, OR, 2.74; 95% CI, 2.42–3.10), and non-ischemic cardiomyopathy (NICM, OR, 4.99; 95% CI, 4.44–5.63). Among carriers, by age 50 years, 24.5% (95% CI, 14.5%–33.4%) developed ACHF, 17.2% (95% CI, 8.8%–24.8%) developed NIHF, and 30.1% (95% CI, 19.5%–40.2%) developed NICM. Higher polygenic risk for heart failure was independently associated with increased risk of ACHF (OR, 1.81; 95% CI, 1.74–1.89), NIHF (OR, 1.66; 95% CI, 1.58–1.75), and NICM (OR, 1.69; 95% CI, 1.59–1.80). Among carriers with elevated polygenic risk, odds of disease were substantially higher than among non-carriers at average polygenic risk (ACHF: OR, 4.71; 95% CI, 4.17–5.32; NIHF: OR, 4.56; 95% CI, 3.99–5.22; NICM: OR, 8.51; 95% CI, 7.44–9.73). Results showed that P/LP variants in cardiomyopathy genes were relatively common in this large, ancestrally diverse cohort, and conferred increased risk of cardiomyopathy and HF, with incomplete but clinically meaningful penetrance. Polygenic risk for HF independently and additively increased disease risk across ancestries. Integrating both may improve risk stratification and enable more precise, equitable care.
2025 Acute Coronary Syndrome Guideline: Missing the Boat on CYP2C19 Genotyping
Cavallari, Larisa H. , Lee, Craig R. , Beitelshees, Amber L. , Stouffer, George A. , Berg, Jurriën M. ten , Broek, Wout W.A. van den, Pereira, Naveen, Sibbing, Dirk , Angiolillo, Dominick J. , Beitelshees, Amber L. , Luzum, Jasmine A , Stouffer, George A , Ten Berg, Jurrien , van den Broek, Wout W A , Pereira, Naveen L , Sibbing, Dirk , Angiolillo, Dominick J , Cavallari, Larisa H , Luzum, Jasmine A.

Mayo Clinic

Journal of the American Heart Association | May 6, 2026 | Volume: 15 | Issue: 10 | Pages: No page available

10.1161/jaha.125.047768 | PMID 42089171 Get It

The 2025 American College of Cardiology/American Heart Association/American College of Emergency Physicians/National Association of Emergency Medical Services Physicians/Society for Cardiovascular Angiography & Interventions acute coronary syndrome guideline focuses on strategies to reduce bleeding risk with antiplatelet therapy yet lacks any recommendation related to CYP2C19 genotyping. The impact of CYP2C19 loss‐of‐function alleles on the effectiveness of clopidogrel is well documented, and although prasugrel and ticagrelor more effectively reduce the risk for atherothrombotic events compared with clopidogrel in patients with a CYP2C19 loss‐of‐function allele, clopidogrel reduces bleeding risk without an increase in atherothrombotic events compared with prasugrel or ticagrelor in those without a loss‐of‐function allele. Accordingly, an American Heart Association Scientific Statement supports CYP2C19 genetic testing before oral P2Y 12 inhibitors are prescribed. This commentary summarizes the evidence in support of CYP2C19 ‐guided P2Y 12 inhibitor selection in the context of other 2025 acute coronary syndrome guideline recommendations and urges future guidelines to incorporate recommendations for CYP2C19 genotyping, especially for those at high bleeding risk.
Very high-dose loop diuretics for worsening heart failure—a randomized pilot trial
Reddy, Yogesh N V, Miranda, William R, Greenlund, Ian M. , Bailey, Kent R, Testani, Jeffrey, Somers, V., Borlaug, Barry A, Pereira, N L, Somers, Virend K. , Charles Jain, C , Oduah, Mary-Tiffany , Adel, Fadi , Somers, Virend K. , Reddy, Yogesh N.V. , Miranda, William R. , Bailey, Kent R. , Testani, Jeffrey M. , Borlaug, Barry A. , Pereira, Naveen L.

Mayo Clinic

European Journal of Heart Failure | March 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ejhf/xuag069 | PMID 41802270 Get It

Prevalence of atrial and ventricular arrhythmias in patients with titin truncating variants across the ventricular morphofunctional phenotypic spectrum
Coderre, Roxanne, Castrichini, M, Neves, R Almeida Lopes, Ackerman, M J, Pereira, Naveen, Giudicessi, J R, Castrichini, Matteo , Garmany, Ramin , Neves, R Almeida Lopes, Ackerman, Michael J. , Giudicessi, John R.

Mayo Clinic

European Heart Journal | February 5, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.2656 Get It

Abstract Background Loss-of-function variants in TTN-encoded titin are the most common genetic cause of dilated cardiomyopathy (DCM). In addition, titin truncating variants (TTNtvs) are over-represented in early-onset atrial fibrillation (AF) and unexplained sudden cardiac arrest/death (SCA/SCD) suggesting that in rare circumstances TTNtvs may cause arrhythmias in a pre-cardiomyopathic electrical phase. Purpose To compare the prevalence of AF, sustained ventricular arrhythmias (VAs) and SCA/SCD between TTNtv-positive patients with genotype-positive but phenotype-negative (G+/P-) disease, non-dilated left ventricular cardiomyopathy (NDLVC) and DCM. Methods Retrospective review of 1,229 patients in our Arrhythmogenic/Dilated Cardiomyopathy Registry was used to identify those with TTNtvs in high proportion spliced-in (>90%) exons classified as pathogenic or likely pathogenic according to current American College of Medical Genetics and Genomics variant classification guidelines. Demographic, electrocardiographic, imaging and outcome data were extracted from the electronic record. After exclusion of those without satisfactory imaging data, each TTNtv-positive patient was classified as having G+/P- disease, NDLVC, or DCM according to the 2023 European Society of Cardiology Guidelines for the management of cardiomyopathies. The prevalence of AF, non-SCA major VA events (sustained VT and appropriate VT/VF-terminating ICD therapies), and SCA/SCD was then compared between the three left ventricular morphofunctional subgroups. Results Overall, 232 TTNtv-positive patients (mean age of 44 ± 17 years; 57% male) were included (average LVEF of 39 ± 17%; 32% with a history of AF; 23% with a history of non-SCA VA event and 6% with a history of SCA). Forty-nine (21%) were G+/P-, 45 (19%) had NDLVC, and 138 (59%) had DCM at the time of their most recent clinical evaluation. As expected, the prevalence of AF was higher in TTNtv-DCM patients when compared to both TTNtv-NDLVC [56/138 (41%) vs. 11/45 (24%); p=0.04] and G+/P- disease [56/138 (41%) vs. 5/49 (10%); p<0.001]. Similarly, the number of patients who experienced a non-SCA major VA event was higher in TTNtv-DCM than either TTNtv-NDLVC [44/138 (32%) vs. 6/45 (9%); p=0.01] or G+/P- disease [44/138 (31%) vs. 4/49 (8%); p<0.001]. Interestingly, no difference in the number of TTNtv-positive patients who experienced a SCA/SCD was observed across subgroups [2/49 (4%) for G+/P-; 2/45 (4%) for NDLVC; and 8/138 (6%) for DCM; p=ns for all comparisons]. Conclusion In patients with TTNtv substrates who were evaluated at a quaternary medical center, the prevalence of AF and major VA events correlates with left ventricular morphology/function with the greatest risk observed in those with DCM. However, the prevalence of AF and major VA events, including SCA, in TTNtv-positive patients with G+/P- and NDLVC disease is not trivial and highlights the ability of TTNtvs to present in a pre-cardiomyopathic electrical phase.
Utility of polygenic risk scores for dilated cardiomyopathy in the general population
Figueiral, M, Jenkins, Gregory D. , Scott, C, Klee, E W, Rodeheffer, R J, Inojosa, J R Medina, Redfield, M M, Burnett, J C, Lopez-Jimenez, F, Sinagra, G, Merlo, M, Pereira, N L, Paldino, Alessia , Figueiral, Marta , Scott, Christopher G. , Rodeheffer, Richard J. , Medina‐Inojosa, José R. , López-Jiménez, Francisco , Sinagra, Gianfranco , Merlo, Marco , Pereira, Naveen L.

Mayo Clinic

European Heart Journal | February 5, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.2658 Get It

Abstract Background Common genetic variation has been linked to an increased risk of developing dilated cardiomyopathy (DCM) in case-control studies. However, the phenotypic profile and biological mechanisms by which genetic background may predispose individuals to DCM and outcomes in the general population remain unclear. Aim The primary objectives of this study were twofold: (1) to validate a DCM polygenic score (PRS-1) based on a prior meta-analysis of case–control genetic association studies [Tadros R et al. Nat Genet (2021)]; and (2) To apply this PRS, along with two recently developed PRSs for DCM [PRS-2 from Zheng SL et al. Nat Genet (2024) and PRS-3 from Jurgens SJ et al. Nat Genet (2024)] to a general population that underwent comprehensive longitudinal phenotypic assessments and had long-term outcomes available. Methods While the PRS-1 was derived from only 13 SNPs, PRS-2 and PRS-3 were generated from 709,534 and 1,072,247 SNPs, respectively with significant overlap between them. These DCM-PRSs were applied to an unselected community-based cohort (n=1897) aged >45 years, who underwent a physical examination, echocardiogram, and blood sample at baseline. Subsequent clinical outcomes were collected over a median 16 year follow-up (IQR: 15-17). Results No significant differences between the quartiles were present in terms of age, sex (48% male), and cardiovascular risk factors (CV-RF) (such as hypertension, diabetes, and coronary artery disease). However, linear regression models demonstrated a significant correlation between all DCM-PRSs and left ventricular (LV) parameters, including LV ejection fraction, LV end-systolic diameter, and LV end-diastolic diameter (Table). Multivariable regression analysis confirmed that these correlations were independent of age, sex, CV-RF, and population stratification (adjusted for the first 10 principal components [PCs]). During follow-up, 47 individuals developed DCM. A logistic regression analysis, using a 3:1 matched cohort of non-DCM vs. DCM individuals based on age and sex and adjusted for the same 10 PCs, found a significant correlation between DCM development and both PRS-1 [OR=2.27 (1.06–4.85), p=0.03] and PRS-3 [OR=2.63 (1.20–5.75), p=0.02], while PRS-2 did not show a significant association [OR=1.85 (0.84–4.06), p=0.12]. No association was found between the DCM-PRSs and heart failure (HF) biomarkers (aldosterone, natriuretic peptides, ST2, Galectin-3) or HF outcomes (all-cause mortality/HF hospitalization). Conclusion PRS-1 for DCM despite being derived from only 13 risk alleles, performs at least as well as the newer and more extensive PRSs, in its correlation with LV function, dimensions, and DCM development (except for PRS-2) in a general population. The absence of correlation between these DCM-PRSs and the renin-angiotensin-aldosterone system or natriuretic peptides suggests that genetic background influences LV traits through mechanisms independent of these biological pathways.
Novel association of NAV3 with dilated cardiomyopathy and its role in cardiac fibrosis
wang, Min, Ghazal, Rachad , Srinivas, Akshatha N. , Nguyen, Thanh Thanh L. , Murthy, Vishakantha , McNamara, D., Skime, Michelle , Batzler, Anthony , Jenkins, Gregory D. , Barlera, Simona, Mestroni, Luisa, Merlo, Marco, Pinet, Florence, Krejčí, Jan, Chaloupka, Anna , Groote, Pascal. De, Weinshilboum, RM, Tschumperlin, Daniel J. , Liu, Duan , Pereira, Naveen, McNamara, Dennis M. , Nguyen, Thanh Thanh L. , Wang, Min , Ghazal, Rachad , Wang, Min , McNamara, Dennis M , Skime, Michelle K , Pileggi, Silvana , Mestroni, Luisa , Pinet, Florence , Krejčí, Jan , Chaloupka, Anna , de Groote, Pascal , Weinshilboum, Richard M. , Tschumperlin, Daniel J , Liu, Duan , Pereira, Naveen L , Pileggi, Silvana , Mestroni, Luisa , Merlo, Marco , Pinet, F , Krejčí, Jan , Groote, Pascal de

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | January 29, 2026 | Volume: 330 | Issue: 3 | Pages: H686-H696

10.1152/ajpheart.00806.2025 | PMID 41609618 Get It

This study uncovers a previously unrecognized role for NAV3 in TGF-β1-driven cardiac fibroblast activation. We show that NAV3 facilitates profibrotic remodeling through noncanonical signaling and cell cycle arrest, independently of SMAD2/3. These findings position NAV3 as a novel regulator of fibroblast phenotype and a potential modulator of cardiac fibrosis.
Longitudinal Peripheral Blood Transcriptomics Reveal Novel Signatures During Cardiac Allograft Rejection
Ghazal, Rachad , Wang, Min, Cao, Jenny Jia Ling, Vyas, Hridyanshu , Liu, Duan , Nair, Asha , Wang, Li , Yip, D., Patel, Parag C., Steidley, D. Eric , Hardaway, Brian , Clavell, Alfredo L., Kushwaha, Sudhir S. , Eisen, Howard J., Pereira, Naveen, Srinivas, Akshatha N. , Steidley, David E, Hardaway, Brian W, Pereira, Naveen L , Liu, Duan , Ghazal, Rachad , Srinivas, Akshatha N., Smith, Byron H. , Yip, Daniel , Patel, Parag C. , Clavell, Alfredo L. , Park, Walter D. , Stegall, Mark D. , Eisen, Howard J.

Mayo Clinic

Transplantation Direct | January 20, 2026 | Volume: 12 | Issue: 2 | Pages: e1882

10.1097/txd.0000000000001882 | PMID 41567756 Get It

Background. Acute cellular rejection (ACR) remains a major cause of morbidity after heart transplantation despite advances in immunosuppression. Whole genome transcriptomic profiling offers a systems-based, unbiased approach to elucidate the molecular mechanisms underlying ACR. However, noninvasive, longitudinal biomarker assessments capable of capturing the temporal dynamics of rejection biology remain scarce. Methods. RNA sequencing of peripheral blood from heart transplant recipients before, during, and after ACR was compared with nonrejection controls. Pathway analysis was conducted using differentially expressed genes (DEGs), and a machine learning approach was applied to assess gene-based prediction of ACR. Results. A total of 235 rejection-specific significant DEGs and 863 postrejection DEGs (false discovery rate < 0.05) were identified. During ACR, DEGs were enriched for T-cell activation/differentiation, apoptosis, and B-cell receptor signaling pathways. By combining the 2 sets of DEGs, a panel of 71 common genes was identified that reflected the significant, longitudinal transcriptomic dynamics of ACR. In an elastic net machine learning–based classifier, DYNLL1 and SERF2 were identified as ACR predictive genes, and achieved a cross-validated area under the receiver operating characteristic curve of 0.63. Conclusions. Peripheral blood transcriptomics identify dynamic temporal responses in ACR including T- and B-cell pathways with potential ACR predictive genes that warrant further investigation.